RenovoRx (RNXT) Competitors

$0.99

-0.01 (-1.00%)

(As of 10/15/2024 ET)

RNXT vs. CYTH, MNPR, NNVC, FGEN, IKT, ADAG, FBLG, CLSD, ACAB, and ELUT

Should you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include Cyclo Therapeutics (CYTH), Monopar Therapeutics (MNPR), NanoViricides (NNVC), FibroGen (FGEN), Inhibikase Therapeutics (IKT), Adagene (ADAG), FibroBiologics (FBLG), Clearside Biomedical (CLSD), Atlantic Coastal Acquisition Corp. II (ACAB), and Elutia (ELUT).

RenovoRx vs.

Cyclo Therapeutics (NASDAQ:CYTH) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

: RenovoRx has a net margin of 0.00% compared to Cyclo Therapeutics' net margin of -1,830.27%. RenovoRx's return on equity of -410.14% beat Cyclo Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Cyclo Therapeutics -1,830.27% -2,741.89% -269.95%
RenovoRx N/A -410.14% -151.52%
: 68.6% of Cyclo Therapeutics shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 29.8% of Cyclo Therapeutics shares are held by insiders. Comparatively, 7.1% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: RenovoRx has lower revenue, but higher earnings than Cyclo Therapeutics. RenovoRx is trading at a lower price-to-earnings ratio than Cyclo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cyclo Therapeutics $1.13M 18.95 -$20.06M -$1.00 -0.75
RenovoRx N/A N/A -$10.23M -$0.72 -1.38
: Cyclo Therapeutics has a beta of -0.38, suggesting that its share price is 138% less volatile than the S&P 500. Comparatively, RenovoRx has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.
: Cyclo Therapeutics presently has a consensus target price of $0.95, suggesting a potential upside of 26.67%. RenovoRx has a consensus target price of $6.13, suggesting a potential upside of 518.62%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts clearly believe RenovoRx is more favorable than Cyclo Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclo Therapeutics
0 Sell rating(s)
2 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.33
RenovoRx
0 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.67
: In the previous week, Cyclo Therapeutics had 2 more articles in the media than RenovoRx. MarketBeat recorded 5 mentions for Cyclo Therapeutics and 3 mentions for RenovoRx. Cyclo Therapeutics' average media sentiment score of 1.16 beat RenovoRx's score of 0.92 indicating that Cyclo Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Cyclo Therapeutics Positive
RenovoRx Positive
: Cyclo Therapeutics received 2 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 71.43% of users gave Cyclo Therapeutics an outperform vote while only 44.44% of users gave RenovoRx an outperform vote.
Company Underperform Outperform
Cyclo Therapeutics Outperform Votes
10
71.43%
Underperform Votes
4
28.57%
RenovoRx Outperform Votes
8
44.44%
Underperform Votes
10
55.56%

Company	Net Margins	Return on Equity	Return on Assets
Cyclo Therapeutics	-1,830.27%	-2,741.89%	-269.95%
RenovoRx	N/A	-410.14%	-151.52%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclo Therapeutics	$1.13M	18.95	-$20.06M	-$1.00	-0.75
RenovoRx	N/A	N/A	-$10.23M	-$0.72	-1.38

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclo Therapeutics	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
RenovoRx	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Company	Overall Sentiment
Cyclo Therapeutics	Positive
RenovoRx	Positive

Company	Underperform	Outperform
Cyclo Therapeutics	Outperform Votes 10 71.43%	Underperform Votes 4 28.57%
RenovoRx	Outperform Votes 8 44.44%	Underperform Votes 10 55.56%

Summary

RenovoRx beats Cyclo Therapeutics on 9 of the 17 factors compared between the two stocks.

Ad Paradigm Press

[Urgent] Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

Get RenovoRx News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNXT vs. The Competition

Export to Excel

Metric	RenovoRx	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.72M	$6.89B	$5.44B	$8.44B
Dividend Yield	N/A	8.76%	4.31%	4.14%
P/E Ratio	-1.65	22.28	121.81	19.49
Price / Sales	N/A	374.60	1,198.32	88.99
Price / Cash	N/A	47.48	38.18	33.49
Price / Book	-3.54	5.65	4.72	4.60
Net Income	-$10.23M	$141.45M	$117.31M	$227.02M
7 Day Performance	-0.93%	5.72%	4.27%	3.69%
1 Month Performance	-12.03%	18.66%	17.10%	12.94%
1 Year Performance	-10.80%	27.03%	31.22%	26.41%

RenovoRx Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNXT RenovoRx	1.8414 of 5 stars	$0.99 -1.0%	$6.13 +518.6%	-9.9%	$23.72M	N/A	-1.65	6	Gap Up
CYTH Cyclo Therapeutics	3.4306 of 5 stars	$0.77 flat	$0.95 +22.7%	-29.9%	$22.21M	$1.08M	-0.88	9	Short Interest ↓ Positive News
MNPR Monopar Therapeutics	3.2876 of 5 stars	$5.50 +6.4%	$22.00 +300.0%	+133.8%	$19.36M	N/A	-2.39	10	Positive News Gap Up
NNVC NanoViricides	N/A	$1.49 +8.8%	N/A	+18.2%	$17.60M	N/A	-2.13	20	News Coverage
FGEN FibroGen	2.5595 of 5 stars	$0.36 +5.9%	N/A	-42.3%	$35.54M	$173.82M	-0.21	486	Analyst Forecast Positive News Gap Up
IKT Inhibikase Therapeutics	2.4684 of 5 stars	$1.47 +13.1%	$15.00 +920.4%	+68.9%	$10.97M	$260,000.00	-0.51	8	Analyst Forecast High Trading Volume
ADAG Adagene	2.5024 of 5 stars	$2.12 -1.9%	$5.00 +135.8%	+56.7%	$93.85M	$18.11M	0.00	260
FBLG FibroBiologics	3.1378 of 5 stars	$2.60 +12.1%	$12.00 +361.5%	N/A	$92.87M	N/A	0.00	10	Short Interest ↑ Gap Down
CLSD Clearside Biomedical	2.2376 of 5 stars	$1.24 -6.1%	$5.17 +316.7%	+38.2%	$92.67M	$7.52M	-2.48	30	Analyst Forecast Gap Down High Trading Volume
ACAB Atlantic Coastal Acquisition Corp. II	N/A	$11.10 flat	N/A	+4.8%	$90.69M	N/A	0.00	4	News Coverage Positive News
ELUT Elutia	2.7607 of 5 stars	$3.70 -1.3%	$10.00 +170.3%	+163.4%	$89.81M	$24.99M	-1.30	180	Short Interest ↑ Gap Down